NRD
RGNX icon

Nebula Research & Development’s Regenxbio RGNX Stock Holding History

Nebula Research & Development’s Portfolio RGNX Stock Details RGNX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q3 		– Sell
-151,293
Closed -$1.24M – 696
2025
Q2 		$1.24M Buy
+151,293
New +$1.27M 0.11% 325

Other funds holding RGNX

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
RG
Redmile Group San Francisco, California $1.49B AUM 208.7% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
AQR Capital Management
AQR Capital Management Greenwich, Connecticut $287B AUM 42.33% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return

Nebula Research & Development's RGNX Position: Q3 2025 in Review

Nebula Research & Development sold out of Regenxbio (RGNX) in Q3 2025, closing a stake of 151,293 shares — an estimated $1.24M sold.

Nebula Research & Development first reported a position in RGNX in Q2 2025 and held it in 1 quarter. The position peaked at $1.24M in Q2 2025. 166 funds tracked by Wall St. Rank hold RGNX as of Q3 2025.

  • Nebula Research & Development reported no remaining Regenxbio position as of Q3 2025 after selling out during the quarter.
  • Nebula Research & Development sold 151,293 Regenxbio shares in Q3 2025, an estimated $1.24M.
  • Nebula Research & Development first reported a position in Regenxbio in Q2 2025 and held it in 1 quarter.
  • Nebula Research & Development's Regenxbio position peaked at $1.24M in Q2 2025.
  • 166 funds tracked by Wall St. Rank held Regenxbio as of Q3 2025.

Based on Nebula Research & Development's 13F filing for Q3 2025.